17
November , 2017
Friday

Email This Post Email This Post

Agreement resolves unlawful marketing of Antipsychotic Drugs Risperdal & Invega

CHICAGO, IL – Illinois Attorney General Lisa Madigan announced a $1.6 billion joint state and federal settlement with Johnson & Johnson and its subsidiary Janssen Pharmaceuticals over its illegal marketing of antipsychotic drugs Risperdal and Invega. Illinois will receive $23.6 million under the agreement.

Madigan, her state counterparts and the federal government alleged that from 1999 to 2005, the companies unlawfully marketed Risperdal for “off-label uses,” or uses not approved by the U.S. Food and Drug Administration (FDA), and made false and misleading statements about the safety and efficacy of the drug. Further, they allege the company engaged in a kickback scheme with health care professionals and pharmacists to promote the use of Risperdal among children, adolescents and older patients, for whom the drug’s usage was not approved by the FDA.

The states further contend that from 2007 through 2009, the companies promoted Invega for off-label uses and made false and misleading statements about the safety and efficacy of Invega.  The companies’ alleged unlawful conduct caused false and fraudulent claims to be submitted to or caused purchases by government funded health care programs, including Illinois’ Medicaid program.
“Janssen illegally marketed its drugs to vulnerable patients, including children and seniors, and fraudulently billed the state’s Medicaid program for these drugs at taxpayers’ expense,” Madigan said.

The investigation resulted from four qui tam actions filed in the U. S. District Court for the Eastern District of Pennsylvania under the federal False Claims Act and related state statutes. Janssen Pharmaceuticals Inc. additionally will plead guilty in federal court to a criminal misdemeanor charge of misbranding Risperdal in violation of the Food, Drug, and Cosmetic Act. As part of the criminal plea, Janssen has agreed to pay an additional $400 million in criminal fines and forfeitures.
As part of the resolution of these matters, the companies also will enter into a Corporate Integrity Agreement with the U.S. Department of Health and Human Services’ Office of the Inspector General, which will closely monitor the company’s future marketing practices.

This case was handled by Madigan’s Medicaid Fraud Bureau working with the National Association of Medicaid Fraud Control Units.
You can leave a response, or trackback from your own site.

Leave a Reply

You must be logged in to post a comment.

Recent Comments

Welcome to CopyLine Magazine! The first issue of CopyLine Magazine was published in November, 1990, by Editor & Publisher Juanita Bratcher. CopyLine’s main focus is on the political arena – to inform our readers and analyze many of the pressing issues of the day - controversial or otherwise. Our objectives are clear – to keep you abreast of political happenings and maneuvering in the political arena, by reporting and providing provocative commentaries on various issues. For more about CopyLine Magazine, CopyLine Blog, and CopyLine Television/Video, please visit juanitabratcher.com, copylinemagazine.com, and oneononetelevision.com. Bratcher has been a News/Reporter, Author, Publisher, and Journalist for 33 years. She is the author of six books, including “Harold: The Making of a Big City Mayor” (Harold Washington), Chicago’s first African-American mayor; and “Beyond the Boardroom: Empowering a New Generation of Leaders,” about John Herman Stroger, Jr., the first African-American elected President of the Cook County Board. Bratcher is also a Poet/Songwriter, with 17 records – produced by HillTop Records of Hollywood, California. Juanita Bratcher Publisher

Recent Posts